Speakers
Davide Gianni
Perman Jorayev
Richard Kuo
Debora Lucarelli
Panel session
For a number of years now, multiomic approaches have promised to revolutionise healthcare monitoring and drug discovery, and we are now entering a phase where many of these promises are starting to be delivered. Join us for a discussion of where the current state of the art is, and what remaining challenges need to be addressed for multiomics to deliver its full potential.
Dr. Davide Gianni is Senior Director Functional Genomics in Discovery Sciences, BioPharmaceuticals R&D at AstraZeneca and is responsible for leading a department comprising of scientists whose aim is to deliver new therapeutic opportunities for Astrazeneca’s therapy areas of interest. Davide joined AZ from Boehringer-Ingelheim in 2015 where, acting as a Research Laboratory Head, he has led a team of scientists aimed at identifying and validating novel target opportunities for Oncology. Earlier in his career, he conducted his postdoctoral studies at The Scripps Research Institute in La Jolla (California) where he focused his research activities on deciphering the contribution of Reactive Oxygen Species (ROS) in mechanisms underlying human diseases including cancer, neurodegeneration and cardiovascular disease. Davide has authored >25 publications and has co-edited the first dedicated Special Issue on Functional Genomics for SLAS Discovery journal. He has played a key role in initiating the partnership with MRC and University of Cambridge for the creation of the Functional Genomics Screening Laboratory (FGSL). He is a member on the MRC advisory board for the UK Functional Genomics Initiative, a JMC member for the Joint AZ/CRUK Functional Genomics Centre and now a member of the JSC for the FGSL. Finally, Davide has been recognized multiple times in his career for his strong scientific contributions to advance biomedical research (2009 Young Scholar Award from the Alzheimer’s association San Diego, the 2013 Boehringer-Ingelheim Golden Award for the discovery of innovative drugs for cancer patients and the 2020 SLAS Discovery Excellence Award).
Perman is an Investor in the Amadeus Early Stage team. Previously, Perman worked at Verve Ventures, establishing their UK office and investing across Health & Bio, AI, Materials, and Quantum.
Perman holds a PhD from University of Cambridge in Chemical Engineering with a research focus on AI-driven autonomous labs for process development. During his PhD, Perman collaborated with multiple pharma companies to develop new drug synthesis workflows.
Perman holds a BSc in Chemistry and Chemical & Biomolecular Engineering from KAIST, Korea with research experience at EPFL, Switzerland and MIT, USA in carbon capture, live cell protein imaging, crude-oil upgrading, and synthetic chemistry.
Debora is an innovator and leader in the field of genomic technologies with medical applications. She joined Tagomics in the role of CTO at the beginning of 2024. Her expertise in the development and commercialisation of genomics-based platform technologies was most recently demonstrated in her role as CEO of Enhanc3D Genomics, where she led the company through three successful funding rounds, technology development and platform commercialisation. In previous roles Debora led biomarker discovery as Director Biomarker Discovery at Biomodal (formerly Cambridge Epigenetix), directed and managed laboratory operations and large population studies as the Head of Laboratory at the MRC Epidemiology (University of Cambridge) and managed a team to advance Oxford Nanopore’s technology
Frances' practice focuses on representing public and private life sciences companies and industry investors in the pharmaceutical, biotech, techbio and medical technology sectors on a broad range of matters, including licensing and other complex commercial and intellectual property arrangements.
She provides pragmatic, commercially driven, and digestible advice to help clients achieve their business objectives and strategic goals.